IGF::OT::IGF NExT Preclinical Toxicology & Pharmacology of Drugs Developed for Cancer Patients, TO#3, Exploratory Studies of CCR4 CART Cells

IGF::OT::IGF NExT 临床前毒理学

• 批准号: 10361380
• 负责人: David McCormick
• 金额: $ 23.86万
• 依托单位: IIT RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-08 至 2021-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10361380
• 关键词: Award; Cancer Patient; Cells; Contracts; Development; Evaluation; In Vitro; Investigation; Malignant Neoplasms; Organ; Pharmaceutical Preparations; Pharmacology and Toxicology; Process; Source; Testing; Tissues; Toxic effect; anti-cancer therapeutic; anticancer activity; pre-clinical; research clinical testing

The test agent is being considered for development as an anticancer therapeutic. The objective of this task was to characterize the target organ toxicities of an investigative agent that might move forward to clinical testing for anticancer activity. The objective of this task was to obtain a source of tissue or cells for in vitro evaluations of toxicity. The information obtained from this investigation was used to identify drugs with the potential to treat cancer.

正在考虑将供试药物开发为抗癌治疗药物。 该任务的目的是表征研究药物的靶器官毒性，从而可能推进抗癌活性的临床试验。 本任务的目的是获得用于体外毒性评价的组织或细胞来源。 从这项研究中获得的信息被用于确定具有治疗癌症潜力的药物。